Advertisement

Insulin resistance, diabetes and Parkinson's disease: The match continues

  • Anna Delamarre
    Affiliations
    Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France

    CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France
    Search for articles by this author
  • Vincent Rigalleau
    Affiliations
    Service de Diabétologie, CHU Bordeaux, 33604, Pessac, France
    Search for articles by this author
  • Wassilios G. Meissner
    Correspondence
    Corresponding author. Service de Neurologie des Maladies Neurodégénératives, Hôpital Pellegrin, CHU Bordeaux, Place Amélie Raba Léon, 33076, Bordeaux Cedex, France.
    Affiliations
    Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France

    CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France

    Service de Neurologie des Maladies Neurodégénératives, CHU Bordeaux, 33000, Bordeaux, France

    Dept. Medicine, University of Otago, Christchurch, and New Zealand Brain Research Institute, Christchurch, New Zealand
    Search for articles by this author
      It is still a matter of debate whether diabetes increases the risk for Parkinson's disease (PD). Altogether, prospective cohort studies suggest an increased risk, while case-control studies have found the opposite [
      • Yue X.
      • Li H.
      • Yan H.
      • Zhang P.
      • Chang L.
      • Li T.
      Risk of Parkinson disease in diabetes mellitus: an updated meta-analysis of population-based cohort studies.
      ,
      • Lu L.
      • Fu D.L.
      • Li H.Q.
      • Liu A.J.
      • Li J.H.
      • Zheng G.Q.
      Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies.
      ]. Having said this, PD patients with concomitant diabetes show more severe disease and more rapid disease progression [
      • Pagano G.
      • Polychronis S.
      • Wilson H.
      • Giordano B.
      • Ferrara N.
      • Niccolini F.
      • Politis M.
      Diabetes mellitus and Parkinson disease.
      ,
      • Ong M.
      • Foo H.
      • Chander R.J.
      • Wen M.C.
      • Au W.L.
      • Sitoh Y.Y.
      • Tan L.
      • Kandiah N.
      Influence of diabetes mellitus on longitudinal atrophy and cognition in Parkinson's disease.
      ,
      • Mollenhauer B.
      • Zimmermann J.
      • Sixel-Doring F.
      • Focke N.K.
      • Wicke T.
      • Ebentheuer J.
      • Schaumburg M.
      • Lang E.
      • Friede T.
      • Trenkwalder C.
      • DeNoPa Study G.
      Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the de novo Parkinson cohort (DeNoPa).
      ]. At the same time, epidemiological studies have reported a reduced incidence of PD in diabetes patients receiving dipeptidyl peptidase-4 inhibitors or thiazolidinediones for their diabetes [
      • Svenningsson P.
      • Wirdefeldt K.
      • Yin L.
      • Fang F.
      • Markaki I.
      • Efendic S.
      • Ludvigsson J.F.
      Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study.
      ,
      • Zhu Y.
      • Pu J.
      • Chen Y.
      • Zhang B.
      Decreased risk of Parkinson's disease in diabetic patients with thiazolidinediones therapy: an exploratory meta-analysis.
      ]. In addition, a small, mono-centric, randomized, placebo-controlled treatment trial has shown a 3.5 point difference after 60 weeks on MDS-UPDRS motor OFF scores in favor of exenatide, a glucagon-like peptide 1 agonist that is approved for the treatment of diabetes [
      • Athauda D.
      • Maclagan K.
      • Skene S.S.
      • Bajwa-Joseph M.
      • Letchford D.
      • Chowdhury K.
      • Hibbert S.
      • Budnik N.
      • Zampedri L.
      • Dickson J.
      • Li Y.
      • Aviles-Olmos I.
      • Warner T.T.
      • Limousin P.
      • Lees A.J.
      • Greig N.H.
      • Tebbs S.
      • Foltynie T.
      Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Parkinsonism & Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Yue X.
        • Li H.
        • Yan H.
        • Zhang P.
        • Chang L.
        • Li T.
        Risk of Parkinson disease in diabetes mellitus: an updated meta-analysis of population-based cohort studies.
        Medicine (Baltim.). 2016; 95: e3549
        • Lu L.
        • Fu D.L.
        • Li H.Q.
        • Liu A.J.
        • Li J.H.
        • Zheng G.Q.
        Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies.
        PloS One. 2014; 9e85781
        • Pagano G.
        • Polychronis S.
        • Wilson H.
        • Giordano B.
        • Ferrara N.
        • Niccolini F.
        • Politis M.
        Diabetes mellitus and Parkinson disease.
        Neurology. 2018; 90: e1654-e1662
        • Ong M.
        • Foo H.
        • Chander R.J.
        • Wen M.C.
        • Au W.L.
        • Sitoh Y.Y.
        • Tan L.
        • Kandiah N.
        Influence of diabetes mellitus on longitudinal atrophy and cognition in Parkinson's disease.
        J. Neurol. Sci. 2017; 377: 122-126
        • Mollenhauer B.
        • Zimmermann J.
        • Sixel-Doring F.
        • Focke N.K.
        • Wicke T.
        • Ebentheuer J.
        • Schaumburg M.
        • Lang E.
        • Friede T.
        • Trenkwalder C.
        • DeNoPa Study G.
        Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the de novo Parkinson cohort (DeNoPa).
        Mov. Disord. 2019; 34: 67-77
        • Svenningsson P.
        • Wirdefeldt K.
        • Yin L.
        • Fang F.
        • Markaki I.
        • Efendic S.
        • Ludvigsson J.F.
        Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study.
        Mov. Disord. 2016; 31: 1422-1423
        • Zhu Y.
        • Pu J.
        • Chen Y.
        • Zhang B.
        Decreased risk of Parkinson's disease in diabetic patients with thiazolidinediones therapy: an exploratory meta-analysis.
        PloS One. 2019; 14e0224236
        • Athauda D.
        • Maclagan K.
        • Skene S.S.
        • Bajwa-Joseph M.
        • Letchford D.
        • Chowdhury K.
        • Hibbert S.
        • Budnik N.
        • Zampedri L.
        • Dickson J.
        • Li Y.
        • Aviles-Olmos I.
        • Warner T.T.
        • Limousin P.
        • Lees A.J.
        • Greig N.H.
        • Tebbs S.
        • Foltynie T.
        Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
        Lancet. 2017; 390: 1664-1675
        • Saaksjarvi K.
        • Knekt P.
        • Mannisto S.
        • Lyytinen J.
        • Heliovaara M.
        Prospective study on the components of metabolic syndrome and the incidence of Parkinson's disease.
        Park. Relat. Disord. 2015; 21: 1148-1155
        • Hogg E.
        • Athreya K.
        • Basile C.
        • Tan E.E.
        • Kaminski J.
        • Tagliati M.
        High prevalence of undiagnosed insulin resistance in non-diabetic subjects with Parkinson's disease.
        J. Parkinsons Dis. 2018; 8: 259-265
        • Sánchez-Gómez A
        • Alcarraz-Vizán G
        • Fernández M
        • Fernández-Santiago R
        • Ezquerra M
        • Cámara A
        • Serrano M
        • Novials A
        • Muñoz E
        • Valldeoriola F
        • Compta Y
        • Martí MJ
        Peripheral insulin and amylin levels in Parkinson’s disease.
        Parkinsonism Relat Disord. 2020; 79: 91-96
        • Kanatsuka A.
        • Kou S.
        • Makino H.
        IAPP/amylin and beta-cell failure: implication of the risk factors of type 2 diabetes.
        Diabetol Int. 2018; 9: 143-157
        • Jackson K.
        • Barisone G.A.
        • Diaz E.
        • Jin L.W.
        • DeCarli C.
        • Despa F.
        Amylin deposition in the brain: a second amyloid in Alzheimer disease?.
        Ann. Neurol. 2013; 74: 517-526
        • Martinez-Valbuena I.
        • Valenti-Azcarate R.
        • Amat-Villegas I.
        • Riverol M.
        • Marcilla I.
        • de Andrea C.E.
        • Sanchez-Arias J.A.
        • Del Mar Carmona-Abellan M.
        • Marti G.
        • Erro M.E.
        • Martinez-Vila E.
        • Tunon M.T.
        • Luquin M.R.
        Amylin as a potential link between type 2 diabetes and alzheimer disease.
        Ann. Neurol. 2019; 86: 539-551
        • Zhu H.
        • Tao Q.
        • Ang T.F.A.
        • Massaro J.
        • Gan Q.
        • Salim S.
        • Zhu R.Y.
        • Kolachalama V.B.
        • Zhang X.
        • Devine S.
        • Auerbach S.H.
        • DeCarli C.
        • Au R.
        • Qiu W.Q.
        Association of plasma amylin concentration with alzheimer disease and brain structure in older adults.
        JAMA Netw Open. 2019; 2e199826
        • Schultz N.
        • Janelidze S.
        • Byman E.
        • Minthon L.
        • Nagga K.
        • Hansson O.
        • Wennstrom M.
        Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer's disease.
        PloS One. 2019; 14e0218561
        • Horvath I.
        • Wittung-Stafshede P.
        Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson's disease.
        Proc. Natl. Acad. Sci. U. S. A. 2016; 113: 12473-12477
        • Martinez-Valbuena I.
        • Amat-Villegas I.
        • Valenti-Azcarate R.
        • Carmona-Abellan M.D.M.
        • Marcilla I.
        • Tunon M.T.
        • Luquin M.R.
        Interaction of amyloidogenic proteins in pancreatic beta cells from subjects with synucleinopathies.
        Acta Neuropathol. 2018; 135: 877-886
        • Sanke T.
        • Hanabusa T.
        • Nakano Y.
        • Oki C.
        • Okai K.
        • Nishimura S.
        • Kondo M.
        • Nanjo K.
        Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients.
        Diabetologia. 1991; 34: 129-132